menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • Study Endpoints
        • Cardiac safety and efficacy endpoint solutions for all phases, anywhere in the world.

        • Collect continuous ECG data in site-based or hybrid trials with our flexible solutions and patient-friendly devices.

        • Collect and centrally analyze accurate, consistent, quality blood pressure data from site-based to hybrid trials.

        • Monitor every heartbeat with precision to assess safety and efficacy throughout your site-based or hybrid clinical trial.

        • Fulfill your ICH E14 requirement early, minimize risk and potentially reduce costs throughout your trial.

        • Leverage our key opinion leaders to understand the complex regulatory landscape while minimizing risk with confidence.

        • Make trials easier to run, faster to launch, more engaging, and accessible to all.

        • Deliver reliable, scalable, and regulatory-ready eCOA for global Central Nervous System (CNS) trials.

        • Deploy early phase oncology trials in as little as 2 weeks with a cost-effective solution.

        • Accelerate your clinical trial setup with pre-validated and configured eCOA assessments.

        • Expert guidance for capturing high-quality, regulatory compliant data from the right participants at the right time.

        • Improve data accuracy and reduce variability in scoring with Clario's training solutions.

        • Accurately monitor for Suicidal Ideation and Behavior using Clario's exclusive self-reported eC-SSRS.

        • Clario is your trusted parter to ensure you get your clinical trial back on track.

        • Accelerate drug development and reduce risk with Clario’s comprehensive medical imaging core lab services.

        • The Clario team includes medical imaging experts and globally recognized key opinion leaders (KOLs) representing multiple disciplines.

        • Clario’s Image Redact AI automatically redacts sensitive patient identifiers from videos, photos and PDFs.

        • Secure accurate results, streamline your processes, and meet your unique needs with our imaging platform.

        • Leverage our full range of medical imaging and diagnostic imaging modalities, including CT Scans, Endoscopy, MRIs, and more.

        • Securely collect, store, and share de-identified images for compliance with 21 CFR Part 11 and EU GDPR standards.

        • Clario's complete solution for measuring objective digital endpoints of mobility with wearable sensor technology.

        • The Opal V2R® is a research grade wearable sensor that delivers meaningful outcomes and richer insights.

        • Explore more than 750 scientific publications that reflect the technical and clinical applications of Clario’s Opal® System.

        • Generate reliable pulmonary data with low variability and high patient compliance.

        • Support high-quality data, guided technique, and AI-enabled spirometry insights.

        • Centralized, on-site pulmonary function testing for clinical trials.

        • Remote spirometry testing for respiratory clinical trials.

        • Assess cough frequency, cough severity, and other lung sounds.

        • Assess the capacity of the lungs for effective gas transfer.

        • Capture daily symptoms and spirometry to demonstrate respiratory safety and efficacy.

        • Effortless, non-spirometry insight into lung health, including small airway function.

        • Monitor spirometry data quality and plausibility with expert clinical specialist validation.

        • Collect objective airway inflammation data.

        • Advanced, cloud-native technologies and clinical trial software to screen, clean, QC and assess complicated data.

        • Collect, centralize and manage participant screening and eligibility data with customized workflows.

        • Boost stakeholder insights with business intelligence (BI) tools, analytics for endpoint and safety risks, and data exchange solutions.

        • Securely collect, store and share compliant images in the cloud to keep clinical trial sponsors and labs informed.

    • Segments
    • Study Phases
    • Technology
  • Therapeutic Areas
    • Cardiovascular & Metabolic Icon RGBCardiovascular & Metabolic
    • Dermatology Icon RGBDermatology
    • Type 2 Diabetes and Obesity iconDiabetes and Obesity
    • Gastroenterology Icon RGBGastroenterology
    • Hepatology Icon RGBHepatology
    • Infectious Disease Icon RGBInfectious Diseases
    • Muskoskeletal Icon RGBMusculoskeletal
    • Neuroscience Icon RGBNeuroscience
      • Neuroscience Indications
    • Oncology Icon RGBOncology
    • Ophthalmology Icon RGBOphthalmology
    • Respiratory Solutions IconRespiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values and Culture
  • Support
    • Customer Support
    • In-Country Customer Support
    • Contact
  • Solutions
    • Study Endpoints
      • Cardiac Solutions
        • Cardiac Solutions
        • Arrhythmia Analysis
        • Blood Pressure Services
        • ECG – On-site to DCT and Phase I-IV
        • Phase I/TQT Cardiac Assessment
        • Regulatory Consultation and Statistical Analysis Expertise
      • Clinical Adjudication
      • eCOA
        • eCOA Clinical Trials – Overview
        • eCOA Neuroscience
        • eCOA Swift – Early Phase
        • eCOA Rapid Start – Assessment Catalog
        • eCOA Science Services
        • Rater, Participant and Caregiver Training
        • Suicidal Ideation
        • eCOA Rescue Studies
        • eCOA Live
        • eCOA Multimedia
      • Medical Imaging
        • Medical Imaging
        • Image Redact AI
        • Imaging Platform
        • Medical Imaging Science Team
        • Modalities
        • SMART Submit
      • Precision Motion
        • Precision Motion for Clinical Trials
        • Precision Motion for Research
        • Precision Motion: Scientific Publications
      • Respiratory Solutions
        • Respiratory Solutions
        • Solutions for Healthcare Providers
        • Site-Based Spirometry
        • Virtual Home Spirometry
        • Cough and Lung Sounds
        • Diffusing Capacity (DLCO)
        • Spirometry and ePROs
        • Oscillometry
        • Scientific Spirometry Quality Review
        • Fractional Exhaled Nitric Oxide (FeNO)
      • Trial Enablement
        • Trial Enablement
        • Eligibility Solution
        • Reporting & Analytics
        • Source Document Manager
    • Segments
      • Biotechs
      • CROs
      • Pharma
      • Site Experience
    • Study Phases
      • Phase I
      • Phase II/III
    • Technology
      • Artificial Intelligence (AI)
      • Endpoint Data Quality Intelligence
      • Hybrid Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Diabetes and Obesity
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
      • Dementias
      • Headache Disorders
      • Movement Disorders
      • Multiple Sclerosis
      • Pain Disorders
      • Psychiatric Disorders
    • Oncology
    • Ophthalmology
    • Respiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values and Culture
  • Support
    • Customer Support
    • In-Country Customer Support
    • Contact
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Get started
    • Log in
    • Get started
  1. Home Resources Blog Articles The importance of clinical design in ClinRO eCOA migration

The importance of clinical design in ClinRO eCOA migration

An expert discussion

  • Written with – Jan Malecki, Ph.D. – Associate Director eCOA Clinical Science at Clario, a part of Thermo Fisher Scientific

Clinician-reported outcome assessments (ClinROs) are central to many clinical trials, particularly in neuroscience, psychiatry and rare disease. Yet moving a ClinRO from paper to a screen does not automatically make it easier to administer or more consistent.

Complex scoring rules, branching logic and differences in rater experience can introduce variability into endpoint data. We spoke with Jan Malecki Ph.D., Associate Director eCOA Clinical Science, Clario a part of Thermo Fisher Scientific, about what sponsors should consider when implementing eClinROs and how clinical expertise can be embedded directly into assessment design.

What is a ClinRO, and how does it differ from a patient-reported outcome?

Jan: A clinician-reported outcome, or ClinRO, is an assessment completed by a trained healthcare professional or clinical rater, based on observation, interviews, clinical judgment or a combination of these.

Unlike a patient-reported outcome (PRO), where the participant reports directly, a ClinRO requires the rater to interpret clinical information before assigning a score. Because this introduces greater potential for variation between raters, a well-designed eClinRO should preserve the instrument’s clinical meaning while supporting consistent, standardized administration across sites and visits.

Why does ClinRO migration require more than simply digitizing the paper assessment?

Jan: A direct electronic reproduction may capture the same responses, but it can preserve many of the same opportunities for error.

A paper assessment may require the rater to remember detailed instructions, apply basal or ceiling rules, refer to previous answers, perform calculations or compare the current rating with baseline information. Some instruments also use normative data, age-based calculations, diagnostic algorithms or several domain scores.

Simply putting those items on a screen still leaves the rater to manage that complexity.

A clinically designed eClinRO can automate appropriate navigation and scoring, provide guidance when it is needed and flag potentially inconsistent responses before submission. That is the difference between simply digitizing an assessment and using technology to support standardized administration.

Do not assume that putting a ClinRO on a screen makes its administration standardized. A clinically designed eClinRO can automate appropriate navigation and scoring, provide guidance when it is needed and flag potentially inconsistent responses before submission. The electronic implementation should reflect the clinical intent of the instrument, the way raters actually work and the points where errors are most likely to occur. Bringing clinical science, technology and real-world assessment experience together can support more consistent administration and help protect endpoint reliability.

What role do Clario’s clinical scientists play?

Jan: Our clinical scientists build the instrument, configure and test the workflow, and refine the implementation as it develops.

Historical review of query data can also show where raters repeatedly encounter problems. If a response pattern frequently leads to a query, for example, the electronic form can prompt the rater to confirm that the responses reflect the intended rating.

Where appropriate, we work with scale authors, licensors and key opinion leaders to clarify the intended administration. The objective is to translate clinical intent into a practical electronic workflow without changing the construct being measured.

Is there evidence that this approach can reduce errors?

Jan: Across several CNS assessments, we show fewer scoring discrepancies or administration failures with eCOA than with paper.

For the Montgomery–Åsberg Depression Rating Scale, rater discrepancy declined from 97% with paper administration to 30% with electronic administration. Reviews with two discrepancies declined from 90% to 13% – an observed relative reduction of up to 86%.

Lower discrepancy rates were also observed across four assessments used in Alzheimer’s disease trials: the CDR, ADAS-Cog, ACDS-ADL-MCI and MMSE.

For the CAPS-5 in PTSD studies, poor-quality or failing administrations declined from 29% with paper to 12% with Clario’s electronic adaptation.

These findings should be considered alongside the methodology and limitations of each analysis. However, the consistent direction of the results suggests that thoughtful electronic design can help reduce predictable administration and scoring problems.

Can you give an example of how clinical design prevented an implementation problem?

Jan: I can give a case study example.

The challenges:

The TETRAS assessment required high-quality video capture so a third-party reviewer could centrally evaluate tremor severity. However, site teams historically struggled with the workflow, which requires raters and videographers to coordinate closely or the video will not always capture the movements or angles needed for reliable review. If the tremor is not clearly visible, the assessment becomes difficult or impossible to score. Additionally, training materials contain critical administration guidance, but raters do not always accurately recall or apply those details during a live participant visit.

The ClinRO design:

eCOA Clinical scientists redesigned the form to support the assessment and reliable video capture in real time. They included videographer instructions directly in the form, including example images to show what needed to be captured. They also incorporated verbatim participant instructions from the manual, helping raters administer the scale consistently with validated practices. In collaboration with KOLs from the TRG group, the team clarified instructions that were known to be difficult to apply in clinical settings. Logic was also added to improve accuracy for a commonly mis-scored item with nuanced scoring criteria.

The impact:

This design reduced the risk of unusable videos, mis-scored items, and delayed central review. It also decreased site burden by making the workflow clearer, less burdensome and helping raters and videographers coordinate more effectively during administration.

How does Clario’s assessment library support ClinRO quality?

Jan: Clario’s library includes more than 1,000 assessments, but its value is not simply its size.

A strong library preserves the work that has gone into the implementation: the clinical workflow, scoring logic, guidance, testing, translations and version control. When a sponsor uses an existing controlled assessment, it can be configured more efficiently than rebuilding it for every study.

It also supports consistency across a development program. Sponsors can reuse the same implementation from early development through later-phase trials, helping reduce unnecessary variation between studies.

What should sponsors ask an eCOA provider about ClinRO design?

Jan: Sponsors should ask who makes the clinical design decisions and whether those experts remain involved during the build.

They should also ask how the provider handles complex branching, basal and ceiling rules, scoring algorithms, historical error patterns, rater guidance and version control.

Most importantly, ask for evidence. A provider should be able to explain not only which features are available, but how those features address known assessment risks and what effect they have had on discrepancies, administration quality or operational burden.

Written with

Jan Malecki headshot

Jan Malecki, Ph.D.

Associate Director, eCOA Clinical Science

Speak with a Clario eCOA expert about your ClinRO strategy.

Get started
Back to articles
Share
Twitter Facebook LinkedIn

Latest articles

See all articles
Article

Beyond data collection: The connected device advantage in clinical trials 

Connected devices collect the data. A connected clinical strategy transforms it into evidence.

Read
Article

When patient advocates take the stage: Insights from the FDA’s 11th Annual Oncology COA Workshop

Insights from inside the workshop

Read
Article

Nonclinical Concentration-QTc Modeling: Strengthening Cardiac Safety Assessment Earlier in Drug Development 

Why nonclinical C-QTc analysis is becoming a critical tool for modern cardiac safety strategies 

Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Get started

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.

Step 1 of 2 - Quick and easy to complete

Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2026 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum